These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1557841)

  • 1. The dangerous ureter.
    Ward JN; Pitts WR; Bard RH
    Urology; 1992 Apr; 39(4):322-6. PubMed ID: 1557841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
    Haase RN; Harving N
    Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
    [No Abstract]   [Full Text] [Related]  

  • 6. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence.
    Schwalb MD; Herr HW; Sogani PC; Russo P; Sheinfeld J; Fair WR
    J Urol; 1994 Aug; 152(2 Pt 1):382-7. PubMed ID: 8015076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Percutaneous Bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ].
    Yamashita S; Yogi Y; Taniguchi K; Morimitsu H; Suzu H; Kanetake H; Saito Y; Kubota S
    Hinyokika Kiyo; 1992 Oct; 38(10):1095-9. PubMed ID: 1481770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG.
    Miller EB; Eure GR; Schellhammer PF
    Urology; 1993 Jul; 42(1):26-30. PubMed ID: 8328123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guérin therapy.
    Kojima Y; Tozawa K; Kawai N; Sasaki S; Hayashi Y; Kohri K
    Int J Urol; 2006 Apr; 13(4):340-4. PubMed ID: 16734847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract.
    Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Nishimura K; Takaha N; Takahara S; Okuyama A
    Eur Urol; 2000 Dec; 38(6):701-4;discussion 705. PubMed ID: 11111187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management.
    Herr HW; Whitmore WF
    J Urol; 1987 Aug; 138(2):292-4. PubMed ID: 3599241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
    Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance of upper urinary tract transitional cell carcinoma: the role of ureteroscopy, retrograde pyelography, cytology and urinalysis.
    Chen GL; El-Gabry EA; Bagley DH
    J Urol; 2000 Dec; 164(6):1901-4. PubMed ID: 11061876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance intravesical bacillus calmette-guerin for superficial transitional cell carcinoma of bladder. A retrospective study.
    Schwalb DM; Addonizio JC; Camilleri J; Choudhury MS; Eshghi M
    Urology; 1990 Sep; 36(3):222-5. PubMed ID: 2392811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should bladder biopsies be performed routinely after bacillus Calmette-Guérin treatment for high-risk superficial transitional cell cancer of the bladder?
    Guy L; Savareux L; Molinié V; Botto H; Boiteux JP; Lebret T
    Eur Urol; 2006 Sep; 50(3):516-20; discussion 520. PubMed ID: 16632184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.
    deKernion JB; Huang MY; Lindner A; Smith RB; Kaufman JJ
    J Urol; 1985 Apr; 133(4):598-601. PubMed ID: 3981707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.